Navigation Links
Sinovac Biotech Ltd. Files Annual Report on Form 20-F
Date:5/1/2009

BEIJING, May 1 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2008 on May 1, 2009. The Annual Report on Form 20-F is now available on the Company's website under the investor relations section at: http://www.sinovac.com/Investors/SECFilings/.

The Company will provide a hard copy of its complete audited financial statements to its shareholders free of charge upon request. Requests for a hard copy of the 2008 annual report can be processed by visiting the Investor Relations section of the Company's website and filling in the complete mailing details on the request form.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM) , Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

        For more information, please contact:

        Helen G. Yang
        Sinovac Biotech Ltd.
        Tel: +86-10-8289-0088 x9871
        Fax: +86-10-6296-6910
        Email: info@sinovac.com

        Investors:
        Amy Glynn/Sara Ephraim
        The Ruth Group
        Tel: +1-646-536-7023/7002
        Email: aglynn@theruthgroup.com
               sephraim@theruthgroup.com

        Media
        Janine McCargo
        The Ruth Group
        Tel: +1-656-536-7033
        Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
2. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
3. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
4. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
5. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
6. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
7. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
8. Sinovac Releases Statement on Healive Vaccine Suspension
9. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
10. Sinovac Named to Deloitte Technology Fast 50 China
11. Sinovac to Participate in Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)...  At the 2017 Health Information Management Systems ... , IBM (NYSE: IBM ) today introduced ... President and CEO Ginni Rometty will ... 8:30-10 am ET, broadcast live on www.ibm.com ... examine the advent of the Cognitive Era and ...
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
Breaking Biology News(10 mins):